Jasper Therapeutics Stock Buy Hold or Sell Recommendation
| JSPR Stock | USD 26.30 1.42 5.12% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Jasper Therapeutics is 'Hold'. Macroaxis provides Jasper Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding JSPR positions. The advice algorithm takes into account all of Jasper Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Jasper Therapeutics' buy or sell advice are summarized below:
Real Value 13.63 | Target Price 7 | Hype Value 25.81 | Market Value 26.3 | Naive Value 26.77 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Jasper Therapeutics given historical horizon and risk tolerance towards Jasper Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Jasper Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Jasper |
Execute Jasper Therapeutics Buy or Sell Advice
The Jasper recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Jasper Therapeutics. Macroaxis does not own or have any residual interests in Jasper Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Jasper Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Solid | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Jasper Therapeutics Trading Alerts and Improvement Suggestions
| Jasper Therapeutics is way too risky over 90 days horizon | |
| Jasper Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (64.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Jasper Therapeutics currently holds about 60.81 M in cash with (52.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.6. | |
| Jasper Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference |
Jasper Therapeutics Returns Distribution Density
The distribution of Jasper Therapeutics' historical returns is an attempt to chart the uncertainty of Jasper Therapeutics' future price movements. The chart of the probability distribution of Jasper Therapeutics daily returns describes the distribution of returns around its average expected value. We use Jasper Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Jasper Therapeutics returns is essential to provide solid investment advice for Jasper Therapeutics.
| Mean Return | 2.16 | Value At Risk | -5.86 | Potential Upside | 14.19 | Standard Deviation | 5.81 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Jasper Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Jasper Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Jasper Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Jasper Therapeutics backward and forwards among themselves. Jasper Therapeutics' institutional investor refers to the entity that pools money to purchase Jasper Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2023-09-30 | 3 M | Nantahala Capital Management, Llc | 2023-09-30 | 2.4 M | Saturn V Capital Management Llc | 2023-09-30 | 1.4 M | Blackrock Inc | 2023-09-30 | 1.3 M | Geode Capital Management, Llc | 2023-09-30 | 904.5 K | Morgan Stanley - Brokerage Accounts | 2023-09-30 | 780.9 K | Mariner Wealth Advisors, Llc | 2023-09-30 | 652.7 K | Scoggin Llc | 2023-09-30 | 508 K | Fernwood Investment Management, Llc | 2023-12-31 | 494.7 K | Velan Capital Investment Management Lp | 2023-09-30 | 11.2 M | Bvf Inc | 2023-09-30 | 9.9 M |
Jasper Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Jasper Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Jasper Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Jasper stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 2.06 | |
β | Beta against NYSE Composite | 1.72 | |
σ | Overall volatility | 5.42 | |
Ir | Information ratio | 0.36 |
Jasper Therapeutics Volatility Alert
Jasper Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Jasper Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Jasper Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Jasper Therapeutics Fundamentals Vs Peers
Comparing Jasper Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Jasper Therapeutics' direct or indirect competition across all of the common fundamentals between Jasper Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Jasper Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Jasper Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Jasper Therapeutics to competition |
| Fundamentals | Jasper Therapeutics | Peer Average |
| Return On Equity | -1.13 | -0.31 |
| Return On Asset | -0.6 | -0.14 |
| Current Valuation | 312.08 M | 16.62 B |
| Shares Outstanding | 15.06 M | 571.82 M |
| Shares Owned By Insiders | 5.01 % | 10.09 % |
| Shares Owned By Institutions | 61.00 % | 39.21 % |
| Number Of Shares Shorted | 451.91 K | 4.71 M |
| Price To Book | 5.34 X | 9.51 X |
| EBITDA | (69.38 M) | 3.9 B |
| Net Income | (64.47 M) | 570.98 M |
| Cash And Equivalents | 60.81 M | 2.7 B |
| Cash Per Share | 1.60 X | 5.01 X |
| Total Debt | 2.79 M | 5.32 B |
| Debt To Equity | 0.07 % | 48.70 % |
| Current Ratio | 9.56 X | 2.16 X |
| Book Value Per Share | 7.03 X | 1.93 K |
| Cash Flow From Operations | (52.07 M) | 971.22 M |
| Short Ratio | 3.51 X | 4.00 X |
| Earnings Per Share | (61.80) X | 3.12 X |
| Target Price | 67.5 | |
| Number Of Employees | 45 | 18.84 K |
| Beta | 2.22 | -0.15 |
| Market Capitalization | 396.18 M | 19.03 B |
| Total Asset | 95.38 M | 29.47 B |
| Retained Earnings | (169.6 M) | 9.33 B |
| Working Capital | 76.56 M | 1.48 B |
| Net Asset | 95.38 M |
Note: Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3 [view details]
Jasper Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Jasper . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Jasper Therapeutics Buy or Sell Advice
When is the right time to buy or sell Jasper Therapeutics? Buying financial instruments such as Jasper Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 785K | 4.4M | 7.3M | 7.6M | Total Assets | 93.7M | 48.4M | 95.4M | 79.4M |
Use Investing Ideas to Build Portfolios
In addition to having Jasper Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Furniture Thematic Idea Now
Furniture
Companies producing and selling home and office furniture. The Furniture theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Jasper Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Jasper Stock analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Jasper Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jasper Therapeutics. If investors know Jasper will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jasper Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (61.80) | Return On Assets (0.60) | Return On Equity (1.13) |
The market value of Jasper Therapeutics is measured differently than its book value, which is the value of Jasper that is recorded on the company's balance sheet. Investors also form their own opinion of Jasper Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Jasper Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jasper Therapeutics' market value can be influenced by many factors that don't directly affect Jasper Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jasper Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jasper Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jasper Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.